ad image

Compugen

1 / 1
Computational Discoveries for Clinical Development of Novel Cancer Therapies
Cancer Therapies

Computational Discoveries for Clinical Development of Novel Cancer Therapies

David Alvaro, Ph.D.; Anat Cohen-Dayag, Ph.D.

Pharma's Almanac

PAP-Q2-20-CL-014Jul 01, 2020
Compugen
FDA

Compugen Announces FDA Clearance of IND Application for COM902

Compugen

PR-M11-19-NI-003Nov 05, 2019
Compugen
Immuno-Oncology

Compugen Presents Update on COM701 Phase 1 Trial at ASCO-SITC Clinical Immuno-Oncology Symposium

Compugen

PR-M03-19-NI-006Mar 04, 2019
Compugen, MedImmune to Collaborate on Bi- and Multi-Specific Antibodies
Strategic Collaboration

Compugen, MedImmune to Collaborate on Bi- and Multi-Specific Antibodies

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-M04-18-NI-007Apr 12, 2018
Selexis SA
Cell-Line

Compugen Has Licensed Selexis’ Cell Line-Based Protein Expression Platform for the Development of Antibody-Based Therapeutics

Selexis SA

PR-M03-18-NI-045Mar 13, 2018
Compugen Advances Lead Anti-TIGIT Monoclonal Antibody to Manufacturing
Drug Development

Compugen Advances Lead Anti-TIGIT Monoclonal Antibody to Manufacturing

Nice Insight

PAO-M11-17-NI-025Nov 16, 2017
1 / 1